ClinicalTrials.gg
CompletedNCT06216054Updated Dec 12, 2024

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

A Phase 1 interventional study of LPM3770164 sustained release tablet and LPM3770164 sustained release tablet simulant in Tardive Dyskinesia and Huntington Disease, sponsored by Luye Pharma Group Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by Luye Pharma Group Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Tardive Dyskinesia with a site in China — 3 open to participants now, 3 under way, none of them phase 3. Tardive Dyskinesia · China.

Started
2023
the only one that year
Phase 1
3 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
4 of 10
Luye Pharma Group Ltd.

Among the 10 studies in Tardive Dyskinesia with a site in China, this one is the only one that started in 2023, is one of 3 in phase 1, and was the 6th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

3 of the 10 studies in Tardive Dyskinesia with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Tardive Dyskinesia with a site in China, or all of them as a file.
02

Study summary

This is a single-center, randomized, double-blind, placebo-controlled, multiple-ascending doses trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for later clinical trials.

03

Conditions studied

  • Tardive Dyskinesia
  • Huntington Disease
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject who voluntarily participate and sign the form;
  2. Healthy male/female volunteers aged 18 to 45 years;
  3. Body weight ≥ 50.0 kg for men and ≥ 45.0 kg for women, and (BMI) 18.5 \~ 26.0 kg/m2, inclusive;
  4. Able to comply with the lifestyle restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a history of allergy to any component of the drug or similar drugs, or allergic constitution;
  2. Subject has a current or past medical history that may affect the clinical trial or dysfunction, including but not limited to the past or current respiratory system, circulatory system, digestive system, urinary system, reproductive system, nervous system, endocrine system, immune system, motor system, blood system, psychiatry/ psychology, dermatology and other clinically serious diseases or chronic diseases; or any other diseases that may interfere with the test results;
  3. Any surgical condition or condition may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects;.
  4. Subject has a history of self-mutilation; or at risk of suicide;
  5. Subject has a history of surgery within 3 months prior to administration, or failure to recover from surgery, or having an expected surgical plan during the trial;
  6. Subject has abnormal vital signs, laboratory abnormalities, and ECGs;
  7. Subject has used any of over-the-counter products within 7 days or prescription medications within 28 days prior to dosing;
  8. Subject positive for surface antigen (HBsAg), antibody (HCV-Ab), antibody (HIV-Ab), or syphilis seroreactivity (Trust);
  9. Subject has a history of alcohol abuse within 1 year or positive alcohol breath test results;
  10. Subject has a history of substance abuse within 1 year or a positive urine drug screen;
  11. Subject who has daily smoking of ≥ 5 cigarettes within 3 months;
  12. Subject who has special requirements for food, cannot comply with the unified diet or have dysphagia;
  13. Subject who has consumption of xanthine-rich foods or beverages (such as tea, coffee, cola, or chocolate) within 3 days prior to administration;
  14. Subject who has consumption of food or beverages containing grapefruit within 7 days prior to administration;
  15. Subject who has participated in other clinical trials within 3 months before administration;
  16. Subject has used blood products or being blood donor or blood loss within 3 months;
  17. Pregnant, lactating women, or positive pregnancy test;
  18. Subject who refusal to , or plan to donate sperm or ovums;
  19. Other conditions which would make participation in the study unsuitable.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    LPM3770164

    LPM3770164 sustained-release tablets will be administrated with multiple doses from 5mg to 30mg on day 1\~10

    Drug: LPM3770164 sustained release tablet

  • Placebo comparator
    Placebo

    LPM3770164 sustained release tablet simulant will be administrated on day 1\~10

    Drug: LPM3770164 sustained release tablet simulant

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse event

    Number of participants with treatment-emergent adverse event will be summarized by Group, System Organ Classification (SOC), Preferred Term (PT), severity and the relationship with treatment.

    Time frame: from baseline to day 37

Secondary outcomes

  1. Peak Plasma Concentration (Cmax)

    Time frame: from day 1 to day 24

  2. Area Under the Curve from time 0 to 24 hours (AUC0-24)

    Time frame: from day 1 to day 24

  3. Area Under the Curve from time 0 to the last measurable concentration (AUC0-t)

    Time frame: from day 1 to day 24

  4. Area Under the Curve from time 0 extrapolated to infinity (AUC0-inf)

    Time frame: from day 1 to day 24

  5. Time to maximum concentration (Tmax)

    Time frame: from day 1 to day 24

  6. Half-life (t1/2)

    Time frame: from day 1 to day 24

  7. ECG QTc Interval

    Time frame: from baseline to day 37

07

Study locations

1 site
  • Shanghai Mental Health Center
    Shanghai, Shanghai Municipality, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Jul 2024, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 22, 2024
StartActual
Dec 19, 2023
Primary completionActual
Jul 29, 2024
CompletionActual
Jul 29, 2024
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06216054
Responsible party
Sponsor
First posted
Jan 22, 2024
Start date
Dec 19, 2023
Primary completion
Jul 29, 2024
Completion
Jul 29, 2024
Last update
Dec 12, 2024

Study contacts

Huafang Li, Doctor
principal investigator · Shanghai Mental Health Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LPM3770164

Start the discussion